TIA is a not-for-profit company limited by guarantee, and is governed by applicable legislation. TIA is overseen by an independent, skills-based Board that meets monthly, and a Governance, Audit and Risk Committee chaired by the Company Secretary that meets every 2 months. TIA is managed day-to-day by a full-time CEO and Program Manager, based at TIA's Brisbane office.
TIA has developed a Strategic Plan for the period 2019-2023 that outlines four strategic aims associated with support of a network of Australian translational research infrastructure.
The 14 facilities supported by TIA are organised into three therapeutic development pipelines, ie. Biologics, Cell and Gene Therapies and Small Molecules. Each of these areas holds regular meetings to discuss matters of mutual interest.
Mr Terry Slater
AM, BSc, BEc, MPH, MAICD, FAIM
Terry has held a number of Board positions in addition to being Chair of TIA including as a Director and Company Secretary for DrinkWise Australia Ltd, Strategic Financial Advisor to the Board of Principals Australia and Chair of the National Food Authority Board. He led the work to establish National Statutory Schemes involving the Chairing of Inter-departmental Committees, and Commonwealth, State and Territory working parties and committees to create the Australian New Zealand Food Authority (ANZFA), Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), the Office of the Gene Technology Regulator (OGTR), Treaty establishing the Australian New Zealand food Authority and the Treaty establishing the future creation of the Australian New Zealand Therapeutic Products Agency He was National Manager of the TGA and CEO of Australians Donate. He has played significant roles in Public Health policy and regulation.
Mr Rob Anderson
Mr Anderson was the Managing Director of Orthogen Australia, which operated in the cell therapies sector. He is also principal of Anderson Business Consultants. Rob has significant experience consulting to government and industry. He has extensive commercial and financial experience in a diverse range of industries and business structures, including as Partner (Audit and Advisory) at Deloitte Touche Tohmatsu.
The Board members are knowledgable individuals with extensive experience in the public, private and not-for-profit sectors. The Board comprises:
Ms Liz Furler
B.A (Social Work), Member of the Public Health Association of Aus
Ms Furler has extensive experience in the health and education sectors. Previous positions include Chief Executive Officer of Principals Australia, Executive Director with the Department of Education and Children’s Services in South Australia, Executive Director of the TRACsa, GM of ANTA (Melbourne) CEO of RACGP, First Assistant Secretary for the Commonwealth Health Services and Public Health Divisions and Principal Adviser to Commonwealth Department of Human Services and Health. Earlier positions included senior roles with the government health sectors of SA, Tasmania and the Commonwealth.
Prof Ross McKinnon
B Pharm (SAIT), B Sc (Hons) (Flinders),
PhD (Flinders), MAICD
Professor McKinnon is an academic pharmacist and pharmacologist with contributions spanning pharmaceutical research, policy and education. Attracting over $26 million, his research has produced more than 150 original papers, multiple patent families and spin-off companies. He was Inaugural Director of both the Sansom Institute (UniSA) and Flinders Centre for Innovation in Cancer (Flinders University). He is currently Dean of Research in the School of Medicine at Flinders.
Ross provided the original vision for Therapeutic Innovation Australia as National Facilitator for the Translating Health Discovery into Clinical Applications project. His international roles include Vice-President of the International Pharmaceutical Federation and Chair of the 5th Pharmaceutical Sciences World Congress held in Melbourne. He is a Director of the Australian Institute of Policy and Science and was recently elected as a Fellow of the Australian Academy of Health and Medical Sciences.
Prof Judith Whitworth
AC MBBS, MD, PhD, DSc (Melb), HonDSc (Glasgow), FRACP, FAICD, FTSE, FAHMS (hon), MD (hon), Syd,
MD (hon) UNSW, D Lett (hon) CDU,
LLD (hon) Melb
Professor Whitworth is an Emeritus Professor at the Australian National University where she was previously Director of the John Curtin Schools of Medical Research. She is a Fellow of the Australian Academy of Technological Sciences and Engineering, the Royal Australasian College of Physicians, and the Australian Institute of Company Directors.
Professor Whitworth has chaired the Medical Research Committee of the NHMRC and is a Past-President of the Australian Society for Medical Research, and the High Blood Pressure Research Council of Australia as well as an Honorary Life Member of the Australian and New Zealand Society of Nephrology.
TIA's management includes skilled and qualified individuals with a range of skills and experience. The CEO is based in Brisbane at the Griffith Institute for Drug Discovery, co-located with Compounds Australia.
Dr Stuart Newman
Chief Executive Officer
Stuart brings with him a diverse range of skills and experience. Since completing a PhD in Antarctic Biology from the University of Tasmania, he has built up considerable experience of science policy, pharmaceutical R&D, grant funding, IP management, business development and commercialisation.
Stuart previously worked with TIA as Queensland Development Manager, where he assisted the development of TIA's Queensland Node, and assisted in establishing the iQDOCs resource and the ATRAX database.
A/Prof Stella Clark AM
Stella Clark joined TIA as Chair of the Australian Therapeutic Pipeline in 2016 and also serves as a Scientific adviser to the Board. She has unique expertise and genuine interest in facilitating scientific endeavours across organisations both public and private. Stella has worked at executive levels and is currently working with TIA to develop the Pipeline.
In 2019 Stella became a member of the Order of Australia for her significant service to medical research as an advocate for improved standards.
Director of Strategic Development, National Biologics Facility
Dr MJ Chua
Ben brings over 20 years of experience in commercializing biologics with a proven track record of developing successful teams and implementing compliant systems for cGMP manufacturing in both Australia and the US. Ben has extensive experience in facility design and start-up, and delivering for his customers in bringing a broad range of vaccines and biologics products through tech transfer from process development through to GMP manufacture and commercialization.
Ben previously worked at Patheon by Thermo Fisher, The University of Queensland, Merck and Co, Inc., and CSL, and is a graduate of the University of New South Wales Bioprocess (Chemical) Engineering.
MJ Chua has diverse experience and background. After graduating with Bachelor of Science degree, she worked as an administration and marketing assistant in a start-up aquaculture company based in Kuala Lumpur, Malaysia. She then pursued a research-based Master's degree.
Subsequently, she worked as a research executive in a market research firm for healthcare and pharmaceutical sectors in the Asia Pacific, Middle East and Africa region. Prior to joining TIA, MJ worked as a Research Fellow at Griffith University.
Dip Primary Teaching, Grad Dip Education
Lesley has been a consultant office manager for TIA since late 2016 after a long career in Education with positions in teaching and administration and tertiary education roles at two Queensland universities. Lesley works part-time and is responsible for the Melbourne office in Collins Street, supporting the Board of Directors and the Governance & Risk committee. Lesley is also a Director of a not-for-profit company dedicated to improving the health and education of orphaned children in Kenya.